Overview

Update
IPO / Stock
Went Public on Oct 9, 2009 / OTCBB:SNGX
Total Equity Funding
$24.29M in 5 Rounds from 10 Investors
Headquarters:
Princeton, NJ
Description:
Soligenix develops biodefense vaccines and therapeutics for the side-effects of cancer treatment and gastrointestinal diseases.
Categories:
Biopharma, Biotechnology, Medical
Website:
http://soligenix.com
Social:

Company Details

Update
Founded:
1987
Aliases:
DOR BIOPHARMA INC, SOLIGENIX, INC.
Contact:
6095388205
Employees:
11 - 50 | 2 in Crunchbase

Soligenix, Inc. is a late-stage research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The Company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early stage development to advanced development and manufacturing.

Funding Rounds (7) - $31.69M

Update
DateAmount / RoundValuationLead InvestorInvestors
Aug, 2015$10M / Undisclosed1
Feb, 2014$300k / Grant0
Jun, 2013$7.1M / Post Ipo Equity1
May, 2013$1.5M / Seed0
Jul, 2010$5.9M / Venture9
Feb, 2009$4.5M / Venture0
Feb, 2009$2.38M / Venture0

Current Team (2)

Update

Board Members and Advisors (1)

Update

Offices/Locations (1)

Update
  • Office

    29 Emmons Drive

    Suite C-10

    Princeton, NJ 08540

    USA

Past Team (1)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos